Basis of Presentation	9 Months Ended
Mar. 31, 2026
Basis of Presentation
Basis of Presentation	2. Basis of Presentation Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the prior year ended June 30, 2025, filed with the SEC on September 5, 2025 (the “Annual Report”), from which the accompanying condensed consolidated balance sheet dated June 30, 2025 was derived. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of March 31, 2026 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and nine months ended March 31, 2026 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Liquidity In accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)”, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. The Company has incurred net losses and generated negative cash flows from operations for many years. For the nine months ended March 31, 2026, the Company incurred a net loss of approximately $22.4 million and had negative cash flows from operations of approximately $17 million. Historically, the Company’s liquidity needs have been met by the sale and issuances of its securities and the issuances of shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), through the sale and exercise of warrants. As of March 31, 2026, iBio had total current assets of approximately $77.3 million, of which approximately $47.6 million was cash and cash equivalents and approximately $27.2 million was investments in debt securities. For the nine months ended March 31, 2026, the Company has an operating capital deficit of $17 million which compares to the $10.7 million operating capital deficit it maintained for the nine months ended March 31, 2025. The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed on an underwritten public offering raising gross proceeds of approximately $50 million and in January 2026, the Company raised gross proceeds of approximately $26 million in a private placement. Additionally, the Company received gross proceeds of approximately $13.8 million from the exercise of warrants during the nine months ended March 31, 2026. Based on the total cash and cash equivalents, and investments in debt securities of approximately $74.8 million at March 31, 2026, and gross proceeds received by the Company of approximately $17 million from warrant exercises in the fourth quarter of fiscal year 2026 (see Note 21 – Subsequent Events for additional information), the Company believes that its current cash position is sufficient to fund its operations for at least 12 months from the date of issuance of these condensed consolidated financial statements.

Basis of Presentation

9 Months Ended

Mar. 31, 2026

2. Basis of Presentation

Interim Condensed Consolidated Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the prior year ended June 30, 2025, filed with the SEC on September 5, 2025 (the “Annual Report”), from which the accompanying condensed consolidated balance sheet dated June 30, 2025 was derived.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of March 31, 2026 and the results of its operations and its cash flows for the periods presented. The results of operations for the three and nine months ended March 31, 2026 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Liquidity

In accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)”, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

The Company has incurred net losses and generated negative cash flows from operations for many years. For the nine months ended March 31, 2026, the Company incurred a net loss of approximately $22.4 million and had negative cash flows from operations of approximately $17 million. Historically, the Company’s liquidity needs have been met by the sale and issuances of its securities and the issuances of shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), through the sale and exercise of warrants. As of March 31, 2026, iBio had total current assets of approximately $77.3 million, of which approximately $47.6 million was cash and cash equivalents and approximately $27.2 million was investments in debt securities. For the nine months ended March 31, 2026, the Company has an operating capital deficit of $17 million which compares to the $10.7 million operating capital deficit it maintained for the nine months ended March 31, 2025.

The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed on an underwritten public offering raising gross proceeds of approximately $50 million and in January 2026, the Company raised gross proceeds of approximately $26 million in a private placement. Additionally, the Company received gross proceeds of approximately $13.8 million from the exercise of warrants during the nine months ended March 31, 2026. Based on the total cash and cash equivalents, and investments in debt securities of approximately $74.8 million at March 31, 2026, and gross proceeds received by the Company of approximately $17 million from warrant exercises in the fourth quarter of fiscal year 2026

(see Note 21 – Subsequent Events for additional information), the Company believes that its current cash position is sufficient to fund its operations for at least 12 months from the date of issuance of these condensed consolidated financial statements.